At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09939 KINTOR PHARMA-B
Trading 12-09 15:53:27
1.940
+0.060
+3.19%
High1.950
Low1.880
Vol981.50K
Open1.900
D1 Closing1.880
Amplitude3.72%
Mkt Cap968.06M
Tradable Cap968.06M
Total Shares499.00M
T/O1.88M
T/O Rate0.20%
Tradable Shares499.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CMB International: Divergence Expected in China's Pharmaceutical Sector, Focus on Stock-Specific Opportunities
ABBISKO-B (02256): Abbisko Announces Phase II Clinical Preliminary Results of Oral PD-L1 Inhibitor ABSK043 Combined with EGFR Inhibitor Furmonertinib for NSCLC at ESMO Asia 2025
GENFLEET-B (02595): GFH375 Phase III Trial for Metastatic Pancreatic Cancer Initiated at First Site – World’s First Oral KRAS G12D Inhibitor Monotherapy vs. Chemotherapy Study
TRANSCENTA-B (06628): Updated Efficacy Data of Osemitamab Triple Therapy for First-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma Presented at ESMO Asia
Pharmaceutical Sector Continues Decline, Bottom-Fishing Funds Return! Medical ETF Hits 4-Month Low with Over 100M Inflows, Hong Kong Innovative Drug Stocks Extend Losses for Fourth Day
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.